Clinical Trial Detail

NCT ID NCT01989585
Title Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

melanoma

Therapies

Dabrafenib + Navitoclax + Trametinib

Dabrafenib + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST